Skip to main content

Advertisement

Figure 6 | Cancer Cell International

Figure 6

From: hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3

Figure 6

Model of impact of hsa-mir-30c on breast cancer cell invasion. Left side: hsa-mir-30c targets and inhibits RUNX2 levels (data not shown and [13]); RUNX2 expressed in metastatic breast cancer cells promotes breast cancer cell invasion [14]. Right side: hsa-mir-30c targets and inhibits NOV/CCN3 levels (Figure 3); NOV/CCN3 inhibits breast cancer cell invasion (Figure 5). Thus the down regulation of NOV/CCN by miR30c contributes to invasive properties. The hsa-mir-30c-RUNX2 pathway is independent of the hsa-mir-30c-NOV/CCN3 pathway (Figure 4). This model of two factors RUNX2 and NOV, each with opposing roles in the invasiveness of metastatic breast cancer cells, are targets of a miR-30c regulatory circuit that reflects the hsa-mir-30c is likely to have many targets that potentially contribute to different properties of breast cancer cells.

Back to article page